MD Anderson and Kymab announce research and development strategic partnership in immuno-oncology

Kymab, a leading human monoclonal antibody biopharmaceutical company, and The University of Texas MD Anderson Oncology Research for Biologics and Immunotherapy Translation (ORBIT) unit today announced a strategic cancer drug discovery and development alliance.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news